
2.8 Emerging Treatments and Future Directions
Our findings highlight key contributors to BPD
pathogenesis, particularly early-onset sepsis, Necrotiz-
ing Enterocolitis (NEC), and Patent Ductus Arteriosus
(PDA). The predictive model is particularly advanta-
geous in optimizing PNCs use by reducing unnecessary
exposure, associated risks and improving overall effi-
cacy. To further enhance the model’s utility, we are
expanding it to include multiclass classification, cate-
gorizing BPD into mild, moderate, and severe classes.
This advancement aims to facilitate targeted interven-
tions and personalized care for high-risk preterm in-
fants.
To facilitate clinical implementation, our predic-
tive model has been developed as a user-friendly web-
based estimator, enabling healthcare providers to ac-
cess and utilize the tool for real-time assessments and
tailored care strategies.
2.8 Emerging Treatments and Future
Directions
Emerging treatments and novel approaches offer
hope for reducing the burden of BPD. According to the
National Institutes of Health, several promising strate-
gies are being explored.
One area of research focuses on stem cell therapy,
specifically mesenchymal stem cells (MSCs), which
have shown potential in repairing lung tissue and re-
ducing inflammation. Preclinical studies have demon-
strated that MSCs can promote lung growth and reduce
fibrosis in animal models of BPD, and early-phase clin-
ical trials are investigating their safety and efficacy in
neonates.
Additionally, new pharmacological agents target-
ing inflammation, oxidative stress, and lung develop-
ment are being developed. Anti-inflammatory agents,
antioxidants, and growth factors that promote alveolar-
ization and vascularization hold promise in preventing
or treating BPD.
Advances in genetic research also pave the way
for precision medicine approaches, enabling targeted
interventions based on an infant’s genetic profile. This
personalized approach may improve outcomes and re-
duce BPD risk.
Moreover, revolutionary changes are on the hori-
zon in neonatology, particularly with artificial womb
technology. By mimicking the intrauterine environ-
ment, this innovation supports extremely preterm in-
fants during critical lung development stages, poten-
tially drastically reducing the need for mechanical ven-
tilation and oxygen therapy – preventing BPD before it
starts.
References
1. Bonadies, L., Zaramella, P., Porzionato, A., Per-
ilongo, G., Muraca, M., & Baraldi, E. (2020).
Present and Future of Bronchopulmonary Dys-
plasia. Journal of Clinical Medicine, 9(5), 1539.
https://doi.org/10.3390/jcm9051539. PMID: 32443685;
PMCID: PMC7290764.
2. Holzfurtner, L., Shahzad, T., Dong, Y., Rekers,
L., Selting, A., Staude, B., Lauer, T., Schmidt,
A., Rivetti, S., Zimmer, K. P., Behnke, J., Bel-
lusci, S., & Ehrhardt, H. (2022). When inflam-
mation meets lung development—An update on
the pathogenesis of bronchopulmonary dyspla-
sia. Molecular and Cellular Pediatrics, 9(1), 7.
https://doi.org/10.1186/s40348-022-00137-z. PMID:
35445327; PMCID: PMC9021337.
3. Zayat, N., Truffert, P., Drumez, E., Duhamel, A.,
Labreuche, J., Zemlin, M., Milligan, D., Maier,
R. F., Jarreau, P. H., Torchin, H., Zeitlin, J.,
Nuytten, A., & EPICE Research Group. (2022).
Systemic Steroids in Preventing Bronchopulmonary
Dysplasia (BPD): Neurodevelopmental Outcome
According to the Risk of BPD in the EPICE Co-
hort. International Journal of Environmental
Research and Public Health, 19(9), 5600. https:
//doi.org/10.3390/ijerph19095600. PMID: 35564997;
PMCID: PMC9106050.
4. Tracy, M. C., & Cornfield, D. N. (2020). Bron-
chopulmonary Dysplasia: Then, Now, and Next.
Pediatric Allergy, Immunology, and Pulmonology,
33(3), 99–109. https://doi.org/10.1089/ped.2020.
1205. PMID: 35922031; PMCID: PMC9354034.
5. Nuthakki, S., Ahmad, K., Johnson, G., & Cuevas
40